Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Corrigendum to "Incidence and clinical parameters associated with eribulin mesylate-induced peripheral neuropathy" [Crit. Rev. Oncol./Hematol. 128 (August) (2018) 110-117].

Zhao B, Zhao H, Zhao J.

Crit Rev Oncol Hematol. 2019 Mar;135:20. doi: 10.1016/j.critrevonc.2019.01.007. Epub 2019 Jan 24. No abstract available.

PMID:
30819442
2.

Corrigendum to "Bartholin gland cancer" [Crit. Rev. Oncol./Hematol. 117 (September) (2017) 1-11].

Di Donato V, Casorelli A, Bardhi E, Vena F, Marchetti C, Muzii L, Panici PB.

Crit Rev Oncol Hematol. 2019 Jan;133:84. doi: 10.1016/j.critrevonc.2017.11.004. Epub 2018 Nov 16. No abstract available.

PMID:
30661661
3.

Corrigendum to "The vicious circle of treatment-induced toxicities in locally advanced head and neck cancer and the impact on treatment intensity" [Crit. Rev. Oncol./Hematol. 116 (2017) 82-88].

Bossi P, Cossu Rocca M, Corvò R, Depenni R, Guardamagna V, Marinangeli F, Miccichè F, Trippa F.

Crit Rev Oncol Hematol. 2017 Nov;119:29. doi: 10.1016/j.critrevonc.2017.09.012. Epub 2017 Sep 28. No abstract available.

PMID:
29065982
4.

Corrigendum to "Evaluation and management of skeletal disease in cancer care" [Crit. Rev. Oncol./Hematol. 120 (December 2017) 217-226].

Kommalapati A, Tella SH, Esquivel MA, Correa R.

Crit Rev Oncol Hematol. 2018 Apr;124:73. doi: 10.1016/j.critrevonc.2018.02.007. Epub 2018 Mar 2. No abstract available.

PMID:
29496392
5.

Corrigendum to "Imaging predictors of treatment outcomes in rectal cancer: An overview" [Crit. Rev. Oncol./Hematol. 129, (September) (2018), 153-162].

ShreeMahadevan L, Zhong J, Venkatesulu B, Kaur H, Bhide S, Minsky B, Chu W, Intven M, van der Heide UA, Triest B, Krishnan S, Hall W.

Crit Rev Oncol Hematol. 2019 Feb;134:71. doi: 10.1016/j.critrevonc.2018.12.008. Epub 2019 Jan 9. No abstract available.

PMID:
30771876
6.

Corrigendum to "Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario" [Crit. Rev. Oncol./Hematol. 122 (February) (2018) 150-156].

Addeo A, Tabbò F, Robinson T, Buffoni L, Novello S.

Crit Rev Oncol Hematol. 2018 Nov 2. pii: S1040-8428(18)30288-9. doi: 10.1016/j.critrevonc.2018.06.018. [Epub ahead of print] No abstract available.

PMID:
30396775
7.

Incidence and clinical parameters associated with eribulin mesylate-induced peripheral neuropathy.

Zhao B, Zhao H, Zhao J.

Crit Rev Oncol Hematol. 2018 Aug;128:110-117. doi: 10.1016/j.critrevonc.2018.06.003. Epub 2018 Jun 12. Review. Erratum in: Crit Rev Oncol Hematol. 2019 Mar;135:20.

PMID:
29958626
8.

Corrigendum to "Endoscopic resection with adjuvant chemo-radiotherapy for superficial esophageal squamous cell carcinoma: A critical review" [Crit. Rev. Oncol./Hematol. 124, April (2018), 61-65].

Kam TY, Kountouri M, Roth A, Frossard JL, Huber O, Mönig S, Zilli T.

Crit Rev Oncol Hematol. 2018 Aug;128:139. doi: 10.1016/j.critrevonc.2018.04.004. Epub 2018 May 4. No abstract available.

PMID:
29731124
9.

Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy.

Vahdat LT, Garcia AA, Vogel C, Pellegrino C, Lindquist DL, Iannotti N, Gopalakrishna P, Sparano JA.

Breast Cancer Res Treat. 2013 Jul;140(2):341-51. doi: 10.1007/s10549-013-2574-2. Epub 2013 Jul 23.

10.

Neuropathy-inducing effects of eribulin mesylate versus paclitaxel in mice with preexisting neuropathy.

Wozniak KM, Wu Y, Farah MH, Littlefield BA, Nomoto K, Slusher BS.

Neurotox Res. 2013 Oct;24(3):338-44. doi: 10.1007/s12640-013-9394-3. Epub 2013 Apr 30.

11.

Erratum to "Lipid metabolism and lung cancer" [Crit. Rev. Oncol. Hematol. 112, April (2017), 31-40].

Salvador MM, de Cedrón MG, Rubio JM, Martínez SF, Martínez RS, Casado E, de Molina AR, Sereno M.

Crit Rev Oncol Hematol. 2019 Jan;133:45. doi: 10.1016/j.critrevonc.2017.10.008. Epub 2018 Nov 14. No abstract available.

PMID:
30661657
12.

Erratum to "Role of radiation therapy in melanomas: Systematic review and best practice in 2015" [Crit. Rev. Oncol./Hematol. 99 (2016) 362-375].

Fort M, Guet S, Husheng S, Calitchi E, Belkacemi Y; AROME (Association of Radiotherapy & Oncology of the Mediterranean arEa; www.aromecancer.org) and TRONE (Transatlantic Radiation Oncology NEtwork).

Crit Rev Oncol Hematol. 2016 Jun;102:144. doi: 10.1016/j.critrevonc.2016.04.008. Epub 2016 May 6. No abstract available.

PMID:
27160735
13.

Erratum to "Cancer-related Fatigue in Adolescents and Young Adults: A Systematic Review of the Literature" [Crit. Rev. Oncol. Hematol. 118 (2017) 63-69].

Nowe E, Stöbel-Richter Y, Sender A, Leuteritz K, Friedrich M, Geue K.

Crit Rev Oncol Hematol. 2017 Dec;120:10-12. doi: 10.1016/j.critrevonc.2017.09.015. Epub 2017 Oct 12. No abstract available.

PMID:
29198323
14.

Erratum to "Role of radiation therapy in non-melanoma cancers, lymphomas and sarcomas of the skin: Systematic review and best practice in 2016" [Crit. Rev. Oncol./Hematol. 99 (2016) 200-213].

Fort M, Guet S, Colson-Durand L, Auzolle C, Belkacemi Y.

Crit Rev Oncol Hematol. 2016 Jun;102:145. doi: 10.1016/j.critrevonc.2016.04.007. Epub 2016 May 6. No abstract available.

PMID:
27160736
15.

Erratum to "Systematic literature review of health-related quality of life in locally-advanced non-small cell lung cancer: Has it yet become state-of-the-art?" [Crit. Rev. Oncol. Hematol., 119 (November) (2017) 40-49].

van der Weijst L, Surmont V, Schrauwen W, Lievens Y.

Crit Rev Oncol Hematol. 2017 Dec;120:234-236. doi: 10.1016/j.critrevonc.2017.10.006. Epub 2017 Oct 19. No abstract available.

PMID:
29055771
16.

[Clinical evaluation of eribulin mesylate for the treatment of metastatic breast cancer].

Matsuzaki H, Tohnosu N, Yoshiwara C, Maruyama T, Tanaka H, Natsume T, Miyazaki A, Sato Y, Ohta T, Yamamoto Y, Aikawa M, Ohtsuka R, Yanagihara A, Iwata K, Shiratori T, Miyazawa Y.

Gan To Kagaku Ryoho. 2014 Apr;41(4):455-9. Japanese.

PMID:
24743360
17.

Incidence and relative risk of peripheral neuropathy in cancer patients treated with eribulin: a meta-analysis.

Peng L, Hong Y, Ye X, Shi P, Zhang J, Wang Y, Zhao Q.

Oncotarget. 2017 Sep 19;8(67):112076-112084. doi: 10.18632/oncotarget.21057. eCollection 2017 Dec 19.

18.

Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice.

Wozniak KM, Nomoto K, Lapidus RG, Wu Y, Carozzi V, Cavaletti G, Hayakawa K, Hosokawa S, Towle MJ, Littlefield BA, Slusher BS.

Cancer Res. 2011 Jun 1;71(11):3952-62. doi: 10.1158/0008-5472.CAN-10-4184. Epub 2011 Apr 15.

19.

Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.

Cortes J, Montero AJ, Glück S.

Cancer Treat Rev. 2012 Apr;38(2):143-51. doi: 10.1016/j.ctrv.2011.03.006. Epub 2011 May 8. Review.

PMID:
21550727
20.

Eribulin mesylate in the treatment of metastatic breast cancer.

Jain S, Cigler T.

Biologics. 2012;6:21-9. doi: 10.2147/BTT.S19811. Epub 2012 Jan 1.

Supplemental Content

Support Center